Thomas Hayman, MD, PhD
Assistant Professor of Therapeutic Radiology
Research & Publications
Biography
News
Locations
Coauthors
Selected Publications
- STING enhances cell death through regulation of reactive oxygen species and DNA damageHayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications 2021, 12: 2327. PMID: 33875663, PMCID: PMC8055995, DOI: 10.1038/s41467-021-22572-8.
- The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stressPhoomak C, Cui W, Hayman TJ, Yu SH, Zhao P, Wells L, Steet R, Contessa JN. The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress. Science Advances 2021, 7: eabc6364. PMID: 33523898, PMCID: PMC7810369, DOI: 10.1126/sciadv.abc6364.
- Whole Genome CRISPR-Cas9 Screen Identifies STING as a Determinant of Intrinsic Radiosensitivity in Head and Neck Squamous Cell CarcinomaHayman T, Baro M, Cui W, Contessa J. Whole Genome CRISPR-Cas9 Screen Identifies STING as a Determinant of Intrinsic Radiosensitivity in Head and Neck Squamous Cell Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s77-s78. DOI: 10.1016/j.ijrobp.2019.06.538.
- Abstract 3935: PLK4 inhibition as a strategy for non-small cell lung cancer radiosensitizationHayman T, Bray M, Mason J, Mak T, Contessa J. Abstract 3935: PLK4 inhibition as a strategy for non-small cell lung cancer radiosensitization. 2019, 3935-3935. DOI: 10.1158/1538-7445.sabcs18-3935.
- Abstract 3935: PLK4 inhibition as a strategy for non-small cell lung cancer radiosensitizationHayman T, Bray M, Mason J, Mak T, Contessa J. Abstract 3935: PLK4 inhibition as a strategy for non-small cell lung cancer radiosensitization. Cancer Research 2019, 79: 3935-3935. DOI: 10.1158/1538-7445.am2019-3935.
- CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell CarcinomaChen WS, Bindra RS, Mo A, Hayman T, Husain Z, Contessa JN, Gaffney SG, Townsend JP, Yu JB. CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers In Oncology 2018, 8: 95. PMID: 29670856, PMCID: PMC5893829, DOI: 10.3389/fonc.2018.00095.
- Increasing Utilization of Stereotactic Radiation Therapy as a Component of Initial Therapy in Metastatic Non–small Cell Lung CancerHayman T, Bledsoe T, Corso C, Lester-Coll N, Park H, Decker R. Increasing Utilization of Stereotactic Radiation Therapy as a Component of Initial Therapy in Metastatic Non–small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e459. DOI: 10.1016/j.ijrobp.2017.06.1702.
- (S032) Investigating CDKN2A Copy Number Loss in HPV- and HPV+ Head and Neck Cancer: A Demonstration of Integrated Genomic and Clinical Analyses Using TCGAChen W, Bindra R, Mo A, Hayman T, Husain Z, Contessa J, Yu J. (S032) Investigating CDKN2A Copy Number Loss in HPV- and HPV+ Head and Neck Cancer: A Demonstration of Integrated Genomic and Clinical Analyses Using TCGA. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e10. DOI: 10.1016/j.ijrobp.2017.02.068.
- CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis.Chen W, Bindra R, Mo A, Hayman T, Husain Z, Contessa J, Gaffney S, Townsend J, Yu J. CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis. Journal Of Clinical Oncology 2017, 35: 6060-6060. DOI: 10.1200/jco.2017.35.15_suppl.6060.
- Receptor Tyrosine Kinases as Targets for Enhancing Tumor RadiosensitivityHayman T, Contessa J. Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity. 2016, 35-55. DOI: 10.1007/978-3-319-40854-5_2.
- Outcomes of resected pancreatic cancer in patients age ≥70.Hayman T, Strom T, Springett G, Balducci L, Hoffe S, Meredith K, Hodul P, Malafa M, Shridhar R. Outcomes of resected pancreatic cancer in patients age ≥70. Journal Of Gastrointestinal Oncology 2015, 6: 498-504. PMID: 26487943, PMCID: PMC4570916, DOI: 10.3978/j.issn.2078-6891.2015.038.
- Pancreatic Cancer Outcomes in Resected Age ≥ 70 Patients Are Comparable to Younger PatientsHayman T, Strom T, Springett G, Balducci L, Hoffe S, Meredith K, Malafa M, Shridhar R. Pancreatic Cancer Outcomes in Resected Age ≥ 70 Patients Are Comparable to Younger Patients. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s361. DOI: 10.1016/j.ijrobp.2014.05.1172.
- The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma CellsHayman T, Wahba A, Rath B, Bae H, Kramp T, Shankavaram U, Camphausen K, Tofilon P. The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells. Clinical Cancer Research 2014, 20: 110-119. PMID: 24198241, PMCID: PMC3947297, DOI: 10.1158/1078-0432.ccr-13-2136.
- The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cellsKahn J, Hayman T, Jamal M, Rath B, Kramp T, Camphausen K, Tofilon P. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro-Oncology 2013, 16: 29-37. PMID: 24311635, PMCID: PMC3870843, DOI: 10.1093/neuonc/not139.
- Abstract 69: In vitro and in vivo tumor cell radiosensitization by the competitive mTOR inhibitor INK128.Hayman T, Kramp T, Camphausen K, Tofilon P. Abstract 69: In vitro and in vivo tumor cell radiosensitization by the competitive mTOR inhibitor INK128. Cancer Research 2013, 73: 69-69. DOI: 10.1158/1538-7445.am2013-69.
- The mTORC1/mTORC2 Inhibitor AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-like CellsKahn J, Hayman T, Camphausen K, Tofilon P. The mTORC1/mTORC2 Inhibitor AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-like Cells. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s697. DOI: 10.1016/j.ijrobp.2012.07.1863.
- Abstract 5727: Competitive inhibition of mTOR results in tumor specific radiosensitizationHayman T, Bae H, Camphausen K, Tofilon P. Abstract 5727: Competitive inhibition of mTOR results in tumor specific radiosensitization. Cancer Research 2012, 72: 5727-5727. DOI: 10.1158/1538-7445.am2012-5727.
- Abstract 2510: eIF4E is a potential tumor specific target for radiosensitizationHayman T, Williams E, Camphausen K, Tofilon P. Abstract 2510: eIF4E is a potential tumor specific target for radiosensitization. Cancer Research 2011, 71: 2510-2510. DOI: 10.1158/1538-7445.am2011-2510.
- 3D Analysis of Tumor Response to Neoadjuvant Chemotherapy (GTX) and Intensity Modulated Radiation Therapy in Patients with Borderline Resectable Pancreatic CancerChuong M, Hayman T, Patel M, Russell M, Malafa M, Hodul P, Springett G, Shridhar R, Hoffe S, Choi J. 3D Analysis of Tumor Response to Neoadjuvant Chemotherapy (GTX) and Intensity Modulated Radiation Therapy in Patients with Borderline Resectable Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s301. DOI: 10.1016/j.ijrobp.2010.07.715.